These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 19951881

  • 1. The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.
    Gobbi PG, Rosti V, Valentino F, Bonetti E, Merli F, Stelitano C, Dondi A, Quarta G, Falorio S, Federico M.
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):425-9. PubMed ID: 19951881
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma.
    Gobbi PG, Valentino F, Danova M, Morabito F, Rovati B, Mammi C, Gentile M, Merli F, Stelitano C, Luminari S, Quintana G, Iannitto E, Brugiatelli M, Federico M.
    Oncol Rep; 2009 Apr; 21(4):1029-35. PubMed ID: 19288005
    [Abstract] [Full Text] [Related]

  • 3. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 4. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D, Rizzo F, Fiore G, Pallotti F, Pulsoni A, Annechini G, Lombardo F, Lenzi A, Gandini L.
    Hum Reprod; 2016 Feb 21; 31(2):263-72. PubMed ID: 26705149
    [Abstract] [Full Text] [Related]

  • 5. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P.
    Hematol Oncol Clin North Am; 2014 Feb 21; 28(1):65-74. PubMed ID: 24287068
    [Abstract] [Full Text] [Related]

  • 6. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.
    J Clin Oncol; 2012 Nov 20; 30(33):4117-23. PubMed ID: 23045592
    [Abstract] [Full Text] [Related]

  • 7. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Loeffler M, Diehl V.
    Cancer Treat Rep; 1987 Dec 20; 71(12):1203-7. PubMed ID: 2446751
    [Abstract] [Full Text] [Related]

  • 8. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2013 Dec 20; 59(2):59-65. PubMed ID: 23814851
    [Abstract] [Full Text] [Related]

  • 9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 10. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG, HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    J Clin Oncol; 2009 Feb 10; 27(5):805-11. PubMed ID: 19124807
    [Abstract] [Full Text] [Related]

  • 11. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 12. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
    Wannesson L, Bargetzi M, Cairoli A, Cerutti A, Heim D, Hess U, Lerch E, Pabst T, Renner C, Samaras P, Zucca E.
    Leuk Lymphoma; 2013 Jan 20; 54(1):36-40. PubMed ID: 22702653
    [Abstract] [Full Text] [Related]

  • 13. ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
    Amin MSA, Brunckhorst O, Scott C, Wrench D, Gleeson M, Kazmi M, Ahmed K.
    Clin Transl Oncol; 2021 Jun 20; 23(6):1067-1077. PubMed ID: 32944834
    [Abstract] [Full Text] [Related]

  • 14. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.
    Anticancer Res; 2009 Feb 20; 29(2):777-83. PubMed ID: 19331235
    [Abstract] [Full Text] [Related]

  • 15. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 16. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Brière J, Clément-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N.
    Cancer Med; 2020 Sep 20; 9(18):6565-6575. PubMed ID: 32710498
    [Abstract] [Full Text] [Related]

  • 17. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
    Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P.
    J Clin Oncol; 2013 Jan 10; 31(2):231-9. PubMed ID: 23150709
    [Abstract] [Full Text] [Related]

  • 18. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O, Hasenclever D, Loeffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    Ann Hematol; 2004 Mar 10; 83(3):176-82. PubMed ID: 15064867
    [Abstract] [Full Text] [Related]

  • 19. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
    Busia A, Laffranchi A, Viviani S, Bonfante V, Villani F.
    Anticancer Res; 2010 Oct 10; 30(10):4381-7. PubMed ID: 21036768
    [Abstract] [Full Text] [Related]

  • 20. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
    Tarasenkova AA, Filatova LV, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2012 Oct 10; 58(1):101-9. PubMed ID: 22629838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.